Four consecutive quarterly beats, averaging 14.7% above expectations—yet this time, the model isn’t backing another beat.
Cardinal Health ($CAH) will report its fiscal 2027 first-quarter results before the U.S. market opens on November 5. The earnings call is at 8:30 a.m. Eastern Time, or 9:30 p.m. Beijing time on November 5.
Here are the expectations:
1. Consensus EPS is about $2.92–$2.94, versus $2.55 in the same quarter last year, up about 14.5%–15.3% year over year;
2. Consensus revenue is about $66.67–$66.96 billion, versus $64.01 billion in the same quarter last year, up about 4.2%–4.6% year over year;
3. Last quarter’s EPS was $2.91, well above the $2.42 consensus at the time. The company has beaten expectations in each of the past four quarters, by an average of about 14.72%;
4. Zacks’ ESP is 0.00%, with a Rank of 3, which under its methodology does not indicate a strong likelihood of a beat. The stock is down 6.3% over the past three months, underperforming both its industry and the broader market.
How to read it: This report isn’t just about whether the headline numbers beat expectations. The key question is whether the specialty business can offset cost pressures in medical distribution. Pharmaceutical and specialty distribution remain the main engines, with generics and specialty expansion supporting profits. But fuel and commodity costs continue to squeeze margins in medical products distribution, and whether tariff-related benefits materialize as expected is another execution risk. A beat, together with full-year EPS guidance of $12.40–$12.60 remaining intact, would keep the story on track. Meeting consensus without the specialty business sustaining its growth would be business as usual. Revenue near the low end of expectations, or distribution profits dragged down by costs to the lower end of guidance, would call for reassessing the outlook with less room for error. Don’t chase the first move before the market opens; wait for the earnings call to break down specialty, medical distribution, and full-year guidance before making a judgment.
Data as of: 2026-11-02 17:04 UTC
For informational purposes only; not investment advice.
Cardinal Health ($CAH) will report its fiscal 2027 first-quarter results before the U.S. market opens on November 5. The earnings call is at 8:30 a.m. Eastern Time, or 9:30 p.m. Beijing time on November 5.
Here are the expectations:
1. Consensus EPS is about $2.92–$2.94, versus $2.55 in the same quarter last year, up about 14.5%–15.3% year over year;
2. Consensus revenue is about $66.67–$66.96 billion, versus $64.01 billion in the same quarter last year, up about 4.2%–4.6% year over year;
3. Last quarter’s EPS was $2.91, well above the $2.42 consensus at the time. The company has beaten expectations in each of the past four quarters, by an average of about 14.72%;
4. Zacks’ ESP is 0.00%, with a Rank of 3, which under its methodology does not indicate a strong likelihood of a beat. The stock is down 6.3% over the past three months, underperforming both its industry and the broader market.
How to read it: This report isn’t just about whether the headline numbers beat expectations. The key question is whether the specialty business can offset cost pressures in medical distribution. Pharmaceutical and specialty distribution remain the main engines, with generics and specialty expansion supporting profits. But fuel and commodity costs continue to squeeze margins in medical products distribution, and whether tariff-related benefits materialize as expected is another execution risk. A beat, together with full-year EPS guidance of $12.40–$12.60 remaining intact, would keep the story on track. Meeting consensus without the specialty business sustaining its growth would be business as usual. Revenue near the low end of expectations, or distribution profits dragged down by costs to the lower end of guidance, would call for reassessing the outlook with less room for error. Don’t chase the first move before the market opens; wait for the earnings call to break down specialty, medical distribution, and full-year guidance before making a judgment.
Data as of: 2026-11-02 17:04 UTC
For informational purposes only; not investment advice.
